Parp
Entity.
- Evidence
- 20 documents · 11 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 1 Sept 2026, last seen 5 Oct 2026
- Measured
- 15% of mentions say something specific about it; the rest only name it
- As of
- 6 Oct 2026
Where this comes from
- Fierce Biotech · 2026-10-05 · Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-05 · Genmab reports Phase I/II data for Rina-S in ovarian cancer (opens the source in a new tab)
- European Medical Journal · 2026-10-04 · Pembrolizumab-Olaparib Delays Ovarian Cancer Progression (opens the source in a new tab)
- Financial Post · 2026-10-04 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-30 · Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-24 · Prospective multicenter study evaluating safety, tolerability and metabolism of niraparib as maintenance for ovarian cancer in women of African ancestry (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-23 · Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance (opens the source in a new tab)
- Latest Science News -- ScienceDaily · 2026-09-23 · This new drug could break cancer’s resistance to treatment (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-21 · ARID1A deficiency identifies molecular alterations and potential therapeutic implications in cervical clear cell carcinoma: an integrated genomic and clini… (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-18 · TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-18 · Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology (opens the source in a new tab)
- Front Cell Dev Biol · 2026-09-01 · PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. (opens the source in a new tab)